Accelerate Preclinical Stroke Research with Clinically Relevant Models

Stroke drug development demands robust, reproducible, and translationally predictive preclinical models. Ace Therapeutics provides a comprehensive portfolio of ischemic and photochemically-induced stroke models to accelerate preclinical stroke research.

Our models are designed to closely recapitulate human stroke pathology, including infarct evolution, blood–brain barrier disruption, neuroinflammation, and long-term functional deficits—allowing you to generate reliable data.

Why Download This Brochure?

This in-depth brochure offers a practical, data-driven overview of how Ace Therapeutics supports stroke research programs worldwide, including:

Validated ischemic stroke models

• Transient and permanent MCAO
• Photochemically-induced stroke
• Endothelin-1 (ET-1)–induced focal ischemias
• Endovascular stroke models

Clinically relevant endpoints

• Infarct size (TTC staining, histopathology)
• Cerebral blood flow and MRI-based imaging
• Blood–brain barrier integrity and edema assessment
• Long-term behavioral and sensorimotor outcomes

Real-world case studies

• Compound efficacy comparisons in transient vs. permanent ischemia
• Longitudinal functional recovery up to 60 days post-stroke
• Longitudinal functional recovery up to 60 days post-stroke

Built for Translation, Flexibility, and Speed

Ace Therapeutics combines deep stroke biology expertise with flexible CRO collaboration models, allowing programs to be tailored to your mechanism of action, therapeutic modality, and development timeline. From small-molecule neuroprotection to cell and regenerative therapies, our multidisciplinary platforms are optimized to support go/no-go decisions with confidence.

Download the Brochure

Discover how Ace Therapeutics' ischemic and photochemically-induced stroke models can strengthen your preclinical package and accelerate your path to the clinic.

You might be interested in...